ADAM17 and COVID-19: Mechanisms underlying increased levels of sACE2 in severe COVID-19 are unclear but could be related to increased ADAM-17 activity [16,24], hyperinflammation (elevated levels of plasma IL-1beta, IL-6 and TNF-alpha) [25], increased renin–angiotensin system activity [26], and lung cell injury [27].